Alendronate Sodium Tablet
Product Images NDC 70518-0033

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 70518-0033). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 01

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 02

The text presents a graph showing the Cumulative Incidence of Hip Fractures in the Three-Year Study of FIT for patients with radiographic vertebral fracture at baseline. The graph compares the Placsbo and Alendronate Sodium treatments over time in months. The Cumulative Incidence is represented as a percentage. Thus, the text provides graphical information related to the study of hip fractures in patients with radiographic vertebral fracture at baseline who were treated with either Placsbo or Alendronate Sodium over three years.*

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 03

This is a description of a study on osteoporosis treatment in postmenopausal women that lasted for three years. The treatment involved a daily dose of Alendronate Sodium 10 mg. The study measured the increase in bone mineral density (BMD) in different regions including the lumbar spine, femoral neck, and trochanter. The data presented in the study is quantified using numbers and notations.*

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 04

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 05

This is a report on BMD (Bone Mineral Density) showing the Mean % Change and Standard Error for various studies conducted on Postmenopausal Women over a period of 2 to 3 years. The results are listed for Lumbar Spine, Femoral Neck, Trochanter and Total Body. There is also some data available on Sodium intake for ENEM?QMB, but the context and meaning of this information is not clear from this text obtained by .*

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 06

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 07

FDA Label Image

Mm2 (Alendronate Sodium 70mg 70518 0033 01)

This is a prescription drug with the brand name "Alendronate Sodium" and the strength is 70 mg. It is a tablet form with a quantity of 12. Its NDC number is 70518-0032-01, and the source NDC number is 69097-0224-76. It is manufactured in Miami, FL 33156 by Cipla USA, Inc. The directions for use are provided in the package insert, and it should be stored at 20-25°C (83-77°F), with possible excursions permitted up to 15-30°C (53-86°F) as per USP standards. The medication should be kept out of the reach of children. It has been repackaged by RemedyRepack Inc., located in Indiana, PA 15701.*

FDA Label Image

Remedy_label (Remedy Label)

This is a prescription medication with the name Alendronate Sodium and strength of 70 mg. The National Drug Code (NDC) is 70518-0032-00, and the manufacturer is Cipla USA based in Miami, FL. The medication is packaged in a bottle with a quantity of 12 tablets. The package insert should be consulted for usage instructions. The medication should be stored at a temperature between 20-25°C (83-77°F) with limited excursions allowed between 15-30°C (53-86°F). This medication should be kept out of reach of children. It was also repackaged by RemedyRepack Inc. located in Indiana, PA.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.